Comparing Guselkumab and Golimumab Treatments for Psoriatic Arthritis
in Patients Not Responding to TNF Inhibitors
Led by University of Pennsylvania · Updated on 2025-10-09
63
Participants Needed
14
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating treatments for patients with psoriatic arthritis PsA who have not responded well to tumor necrosis factor inhibitors TNFi. The trial aims to find out if switching to guselkumab, a selective interleukin 23 inhibitor IL23i, is more effective than switching to a second TNFi, golimumab. This is the first study to compare these treatment switches in PsA patients and will focus on those who have an inadequate response to TNFi in a real-world clinical setting.
Participants will be randomly assigned to one of three treatment groups guselkumab 100mg every 4 weeks, guselkumab 100mg every 8 weeks, or golimumab 50mg every 4 weeks. Both medications are given as subcutaneous injections. The study is open-label, meaning both patients and researchers know which treatment is given. The trial will continue for 12 months to assess treatment effectiveness.
Throughout the study, participants will be monitored for disease activity using measures like cDAPSA low disease activity and Investigator Global Assessment of Psoriasis. Additional assessments include minimal disease activity, quality of life questionnaires, fatigue, and resolution of symptoms such as dactylitis and enthesitis. Safety and treatment response will be evaluated regularly, with the main outcomes measured at 6 and 12 months.
CONDITIONS
Brief Title
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
Research Team
S
Sarah Gillespie
S
Study Coordinator
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Guselkumab (100 mg q4w or q8w)
Golimumab 50 mg q4w
Other guideline‑recommended therapy
What it is
An investigational IL‑23p19 inhibitor given subcutaneously every 4 or 8 weeks
An active TNF‑inhibitor comparator strategy using subcutaneous golimumab 50 mg every 4 weeks
Other biologic or targeted synthetic DMARDs recommended after TNF inhibitor failure
Role in trial
Investigational treatment arms
Active comparator arm
Typical next‑line treatments outside the study
Primary use
To reduce disease activity in PsA patients who did not adequately respond to an initial TNF inhibitor
To assess effectiveness of another TNF inhibitor in TNFi inadequate responder PsA population
To manage PsA after TNF inhibitor failure using an approved biologic or tsDMARD
How it is given or performed
Subcutaneous injection every 4 or 8 weeks depending on dosing cohort
Subcutaneous injection every 4 weeks
Subcutaneous or oral dosing based on chosen agent (eg IL‑17 biologic or oral tsDMARD)
Evidence status
Under evaluation in this randomized trial; prior phase 3 evidence exists for TNFi‑IR cohort (eg COSMOS)
Golimumab efficacy in PsA established in prior studies
Evidence supports benefit of IL‑17, IL‑23 inhibitors or tsDMARDs after TNFi failure
Important risks
Safety profile under evaluation; prior safety data from COSMOS trial exist
Known TNFi class risks including infection and injection reactions
Open‑label design may introduce bias; long‑term outcomes pending
Comparator is another biologic rather than placebo, so relative differences may be modest
Heterogeneity in real‑world comparator agents may affect direct relevance
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years - 80Years
All Genders
Eligibility Criteria
You may qualify if you...
Adults aged 18 to 80 years
Diagnosis of psoriatic arthritis meeting CASPAR criteria
Active psoriatic arthritis with at least one swollen joint
cDAPSA score of 10 or higher (with specific criteria based on psoriasis presence)
Currently using or previously used only one TNF inhibitor with inadequate or lost response
Stable dose of up to two oral small molecule or conventional synthetic DMARDs for at least 4 weeks
Stable dose of NSAIDs, low-dose glucocorticoids (less than 10 mg daily), or topical psoriasis medications for at least 4 weeks
You will not qualify if you...
Previous use of golimumab or any non-TNF biologic therapy except TYK2 inhibitors
History of serious adverse events preventing TNF inhibitor use, including drug-induced lupus, allergic reactions, serious infections, heart failure symptoms, or demyelination
Use of moderate to high dose glucocorticoids (more than 10 mg daily)
Meeting primary endpoint criteria at baseline (low disease activity or clear/almost clear psoriasis)
Currently pregnant or actively trying to conceive
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 12 months
Participants receive either guselkumab or golimumab through subcutaneous injections as part of their treatment for psoriatic arthritis.
Regular dosing visits every 4 or 8 weeks depending on assigned treatment arm
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Similar Trials
Randomized Double-Blind Trial Evaluating TQH3906 Capsules Versus Placebo and Active Drug in Adults with Active Psoriatic Arthritis
Phase IIIII Study of Picankibart Injections for Adults with Active Psoriatic Arthritis
Evaluating the Effects of Zasocitinib Compared to Placebo and Active Treatment in Adults with Active Psoriatic Arthritis Not Previously Treated with Biologic Medicines
Multicenter Open-label Study to Measure Bimekizumab Levels in Breast Milk of Mothers Receiving Bimzelx Treatment
Randomized Study of Upadacitinib Versus Placebo for Treating Active Psoriatic Arthritis with Spondyloarthritis Features
A Phase 1 Study Comparing Bimekizumab Given Intravenously or by Injection in Adults with Active Psoriatic Arthritis or Axial Spondyloarthritis
International Observational Study on Long-Term Use of Risankizumab Compared to Other Advanced Treatments for Adults With Psoriatic Arthritis
Biobank Study for Patients with Chronic Inflammatory Rheumatism and Osteoporosis at Toulouse University Hospital
Study of Card14 gene Polymorphism and Its Effect on Methotrexate Treatment in Egyptian Patients with Moderate to Severe Psoriasis and Psoriatic Arthritis
Long-Term Extension Study Evaluating Safety and Efficacy of Zasocitinib in Adults with Active Psoriatic Arthritis Previously Treated in Parent Studies
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Guselkumab versus golimumab in patients with active psoriatic arthritis and inadequate response to an initial tumor necrosis factor inhibitor: study protocol for EVOLUTION, a pragmatic, phase 3b, open-label, randomized, controlled effectiveness trial.
Alexis Ogdie, Soumya M Reddy, Sarah H Gillespie...